A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis

This study will evaluate the role of mass-based response testing (MRT) to select and deliver personalized hyperthermic intraperitoneal chemotherapy (HIPEC) regimens to patients with peritoneal metastasis (PM) from high-grade appendiceal adenocarcinomas (HGAA) and colorectal cancer (CRC).

Trial Details

NCT ID
NCT07291180
Phase
NA
Sponsor
Yale University
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Mass-based response testing (MRT)
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816

Key Eligibility Criteria

  • Has histologically confirmed peritoneal metastases with primary diagnosis of AJCC 8th Edition Stage IV
  • Appendiceal adenocarcinoma (moderately/poorly differentiated, and/or signet ring cell tumors)
  • Colorectal adenocarcinoma
  • Suspected colon, small bowel, or appendiceal adenocarcinoma in setting of unknown primary

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →